Quintiles posts another $1B quarter and dials up its expectations

Quintiles CEO Tom Pike

Quintiles ($Q), the world's largest CRO, is rolling toward its biggest year yet on the heels of a fourth straight quarter with more than $1 billion in sales.

The company grew its year-over-year revenue by about 14%, grossing roughly $1.1 billion on the way to $92.7 million in net income, a 39% jump. Quintiles' product development segment leaped 8% to $771.4 million and rounded out the quarter with $1.27 billion in net new business, while its smaller healthcare services business soared 33% to $289.6 million and signed $244 million in new contracts.

For the full year, Quintiles is projecting slightly less than previously guided on the revenue front, lowering its outlook by about 1% to $4.2 billion to reflect currency fluctuations and setting itself up for a 10% jump over 2013. However, the company has lifted its full-year earnings guidance to between $2.61 and $2.68 per share, which would amount to a 30% increase over last year at the high end.

On the whole, Quintiles' net new business jumped 13%, giving it a book-to-bill ratio of 1.42 for the quarter and paving the way for further growth, CEO Tom Pike said.

"Quintiles is a story of consistent performance with a focus on industry leadership, and I am proud to report that this story continued in the third quarter of 2014," Pike said in a statement. "... [N]et new business allowed Quintiles to keep its industry-leading backlog of $10.75 billion. Our strong performance continues to strengthen our platform which allows us to capitalize on strategic priorities and create value for our customers and investors."

- read the results

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.